Gut Microbiota Correlates With Clinical Responsiveness to Erythropoietin in Hemodialysis Patients With Anemia

Gut Microbiota Correlates With Clinical Responsiveness to Erythropoietin in Hemodialysis Patients With Anemia

The main treatment for renal anemia in end-stage renal disease (ESRD) patients on hemodialysis is erythropoiesis (EPO). EPO hyporesponsiveness (EH) in dialysis patients is a common clinical problem, which is poorly understood. Recent searches reported that gut microbiota was closely related to the o...

Full description

Bibliographic Details
Main Authors:	Yifan Zhu, Yuyan Tang, Haidong He, Ping Hu, Weiqian Sun, Meiping Jin, Lishun Wang, Xudong Xu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Series:	Frontiers in Cellular and Infection Microbiology
Subjects:	gut microbiota ESRD (End Stage Renal Disease) Anemia EPO hyporesponsiveness hemodialysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fcimb.2022.919352/full

Similar Items

Lower serum magnesium level is an important risk factor for erythropoiesis-stimulating agents hypo-responsiveness in hemodialysis patients
by: Hayam Hebah, et al.
Published: (2025-02-01)

A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness
by: Jie Liu, et al.
Published: (2024-05-01)

Erythropoietin hyporesponsiveness among egyptian hemodialysis patients
by: Salah Eldin Khedr PhD, et al.
Published: (2017-06-01)

The Role of Erythropoietin in Preventing Anemia in the Premature Neonate
by: Oana Cristina Costescu, et al.
Published: (2023-11-01)

Severe Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Patients on Chronic Hemodialysis—Reconsidering the Relationship with Thrombo-Inflammation and Oxidative Stress
by: Srdjan Nikolovski, et al.
Published: (2024-10-01)

Short-term effect of low-dose roxadustat combined with erythropoiesis-stimulating agent treatment for erythropoietin-resistant anemia in patients undergoing maintenance hemodialysis
by: Qiaoying Xu, et al.
Published: (2024-07-01)

Erythropoietin for the treatment of anemia in patients with hematologic disorders
by: R. A. Podgurskaya, et al.
Published: (2022-11-01)

Sustained response to erythropoietin for anemia in NK-cell large granular lymphocytosis: A brief case report
by: Tendai Kwaramba, et al.
Published: (2022-01-01)

Evaluation of salivary flow rate, pH, and buffer capacities in end-stage renal disease patients versus control – A prospective comparative study
by: Tanoj Kumar, et al.
Published: (2020-01-01)

Emergency department visits for hemodialysis by insurance status in the United States
by: Julianna West, et al.
Published: (2022-04-01)

Relationship between gut microbiota and vascular calcification in hemodialysis patients
by: Wen-Han Bao, et al.
Published: (2023-12-01)

Comparative effectiveness of erythropoietin alpha and beta in hemodialysis patients: a single-center prospective observational study
by: Muhammad Nadeem Ahsan, et al.
Published: (2021-11-01)

The prebiotic effects of soluble dietary fiber mixture on renal anemia and the gut microbiota in end-stage renal disease patients on maintenance hemodialysis: a prospective, randomized, placebo-controlled study
by: Yang Li, et al.
Published: (2022-12-01)

Cardiovascular events by different target hemoglobin levels in ESA-hyporesponsive hemodialysis patients: a multicenter, open-label, randomized controlled study
by: Kosaku Nitta, et al.
Published: (2022-12-01)

Prevalence of depression in patients with end-stage renal disease undergoing hemodialysis in Saudi Arabia: A cross-sectional study
by: Lujain Sallam, et al.
Published: (2022-08-01)

Usage of the Anemia Control Model Is Associated with Reduced Hospitalization Risk in Hemodialysis
by: Mario Garbelli, et al.
Published: (2024-09-01)

Assessing the effect of oral activated vitamin D on overall survival in hemodialysis patients: a landmark analysis
by: Jo-Yen Chao, et al.
Published: (2018-11-01)

The future of dialysis treatment: wearable artificial kidneys (WAKs)
by: Rameez Imtiaz, et al.
Published: (2017-06-01)

Mucocutaneous Changes in End-Stage Renal Disease under Regular Hemodialysis - A Cross-Sectional Study
by: Asmaa A. Ras, et al.
Published: (2023-04-01)

“Ideal” parathyroid hormone in erythropoietin‐stimulating agents‐resistant anemia
by: Bilal Ashraf, et al.
Published: (2022-02-01)

Synergistic deterioration of prognosis associated with decreased grip strength and hyporesponse to erythropoiesis-stimulating agents in patients undergoing hemodialysis
by: Shizuka Kobayashi, et al.
Published: (2022-12-01)

Association of Dialysis Adequacy, Physical and Emotional Symptoms with Erythropoietin-stimulating agent Responsiveness in Iraqi Patients Undergoing Hemodialysis
by: Salar Ahmed, et al.
Published: (2024-01-01)

Correlation analysis of systemic inflammatory response index with erythropoietin hyporesponsiveness and clinical prognosis in maintenance hemodialysis patients
by: Li Chun-min, et al.
Published: (2025-02-01)

Relationship between Dialysis Adequacy and Fatigue in Patients on Maintenance Hemodialysis
by: Sri Suparti, et al.
Published: (2020-04-01)

Efficacy of Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitors in Renal Anemia: Enhancing Erythropoiesis and Long-Term Outcomes in Patients with Chronic Kidney Disease
by: Yukina Yoshida, et al.
Published: (2024-12-01)

Decrease in Escherichia-Shigella in the gut microbiota of ESKD patients undergoing maintenance hemodialysis
by: Yunlong Qin, et al.
Published: (2025-02-01)

Calcium homeostasis in red blood cells of dialysis patients   in dependence of erythropoietin treatment
by: Jue eWang, et al.
Published: (2014-01-01)

Evaluation of Erythropoietin Stimulating Agent’s Responsiveness and Associated Factors in Hemodialysis Patients with Anemia
by: Salar Ahmed Alzubaidy, et al.
Published: (2024-09-01)

PHARMACO-ECONOMICBENEFITS OF CORRECTION OF ANEMIA WITH CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR:HEMODIALYSIS VSHEMODIAFILTRATION
by: V. Novakivskyy
Published: (2017-03-01)

Comparison between two treatment protocols with recombinant Human Erythropoietin (rHuEpo) in the treatment of late anemia in neonates with Rh-Isoimmunization
by: A.A. Zuppa, et al.
Published: (2012-08-01)

Association of Erythropoietin, Adiponectin and Leptin levels with Anemia in uremic diabetic patients (Under hemodialysis):
by: Salim M. Al-Rubaâe, et al.
Published: (2011-01-01)

Clinical Features and Quality of Life in End Stage Renal Disease Patients Undergoing Hemodialysis Twice A Week Compared to Thrice A Week
by: Fitri Imelda, et al.
Published: (2017-09-01)

Prescribing and Safety of Direct-Acting Oral Anticoagulants Compared to Warfarin in Patients with Atrial Fibrillation on Chronic Hemodialysis
by: Estella Davis, et al.
Published: (2020-03-01)

Engaging clinicians and patients to assess and improve frailty measurement in adults with end stage renal disease
by: Sarah Van Pilsum Rasmussen, et al.
Published: (2018-01-01)

Erythropoietin treatment and osteoporotic fracture risk in hemodialysis patients: A nationwide population-based study
by: Ching-Yu Lee, et al.
Published: (2024-12-01)

Changes in serum sodium concentration during hemodialysis is a predictor of mortality and cardio-cerebrovascular event
by: Qixing Liu, et al.
Published: (2024-12-01)

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state
by: Amit A. Joharapurkar, et al.
Published: (2022-01-01)

Patient Survival Between Hemodialysis and Peritoneal Dialysis Among End-Stage Renal Disease Patients Secondary to Myeloperoxidase-ANCA-Associated Vasculitis
by: Xueqin Wu, et al.
Published: (2022-01-01)

The Frequency of Resistance to Synthetic Erythropoietin and Its Risk Factors among Chronic Hemodialysis Patients in Kerman
by: Abbas Etminan, et al.
Published: (2018-01-01)

Identification of Gut Microbiome Signatures Associated with Indole Pathway in Tryptophan Metabolism in Patients Undergoing Hemodialysis
by: Jih-Kai Huang, et al.
Published: (2024-05-01)